Sinocelltech Group Ltd (688520) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sinocelltech Group Ltd (688520) has a cash flow conversion efficiency ratio of 0.137x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-100.18 Million ≈ $-14.66 Million USD) by net assets (CN¥-730.66 Million ≈ $-106.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Sinocelltech Group Ltd for the company's overall valuation and market capitalisation.
Sinocelltech Group Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Sinocelltech Group Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sinocelltech Group Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sinocelltech Group Ltd ranked by their cash flow conversion efficiency. Explore 688520 cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Merchants Securities Co. Ltd
F:195H
|
0.139x |
|
Western Metal Materials Co Ltd
SHE:002149
|
0.000x |
|
Kayne Anderson MLP Investment Closed Fund
NYSE:KYN
|
0.011x |
|
Selcuk Ecza Deposu Ticaret ve Sanayi AS
IS:SELEC
|
-0.056x |
|
Diamond Power Infrastructure Limited
NSE:DIACABS
|
0.340x |
|
Beacon Financial Corporation
NYSE:BBT
|
-0.005x |
|
Sh Belling
SHG:600171
|
0.055x |
|
An Hui Wenergy Co Ltd
SHE:000543
|
0.106x |
Annual Cash Flow Conversion Efficiency for Sinocelltech Group Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Sinocelltech Group Ltd from 2016 to 2024. View current stock price of Sinocelltech Group Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥134.94 Million ≈ $19.75 Million |
CN¥125.12 Million ≈ $18.31 Million |
0.927x | +47.52% |
| 2023-12-31 | CN¥-605.81 Million ≈ $-88.65 Million |
CN¥-380.80 Million ≈ $-55.72 Million |
0.629x | -64.42% |
| 2022-12-31 | CN¥-242.19 Million ≈ $-35.44 Million |
CN¥-427.91 Million ≈ $-62.62 Million |
1.767x | -52.70% |
| 2021-12-31 | CN¥-230.99 Million ≈ $-33.80 Million |
CN¥-862.82 Million ≈ $-126.26 Million |
3.735x | +508.95% |
| 2020-12-31 | CN¥588.36 Million ≈ $86.10 Million |
CN¥-537.41 Million ≈ $-78.64 Million |
-0.913x | +93.45% |
| 2019-12-31 | CN¥34.80 Million ≈ $5.09 Million |
CN¥-485.10 Million ≈ $-70.99 Million |
-13.938x | -477.54% |
| 2018-12-31 | CN¥-23.84 Million ≈ $-3.49 Million |
CN¥-88.02 Million ≈ $-12.88 Million |
3.692x | +764.28% |
| 2017-12-31 | CN¥167.84 Million ≈ $24.56 Million |
CN¥-93.28 Million ≈ $-13.65 Million |
-0.556x | -10.91% |
| 2016-12-31 | CN¥80.38 Million ≈ $11.76 Million |
CN¥-40.28 Million ≈ $-5.89 Million |
-0.501x | -- |
About Sinocelltech Group Ltd
Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, and vaccines in China. The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A; Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell… Read more